Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. [electronic resource]
Producer: 19980424Description: S98-106 p. digitalISSN:- 0002-8703
- Abciximab
- Acute Disease
- Angioplasty, Balloon, Coronary
- Antibodies, Monoclonal -- economics
- Coronary Disease -- economics
- Cost-Benefit Analysis
- Dose-Response Relationship, Drug
- Double-Blind Method
- Follow-Up Studies
- Humans
- Immunoglobulin Fab Fragments -- economics
- Infusions, Intravenous
- Platelet Aggregation Inhibitors -- economics
- Prospective Studies
- Risk Factors
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.